INTERCEPT is not approved for sale in the US and certain other countries.
News & Features -
-
ISBT 2013 Amsterdam
(May 15) More
-
Cerus Announces FDA Agreement on Modular Premarket Approval (PMA) Application Submission Process for INTERCEPT Platelets
(Apr 24) More
-
Swissmedic and Swiss Red Cross Present National Haemovigilance Data Showing Favourable Safety Profile for INTERCEPT-Treated Platelet Components
(Apr 03) More
-
Cerus Signs INTERCEPT Platelet Agreements With Two Key Blood Component Suppliers in Germany and Austria
(Mar 15) More
A Single Pathogen Inactivation System for Both Platelets and Plasma
The INTERCEPT Blood System™ is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. It is the first system available to treat both platelets and plasma, and simplifies processing by utilizing the same illumination device, process and active compound. This synergistic approach is designed to meet blood center requirements for efficiency, performance and compatibility with both whole blood and apheresis collections. More |
|
|
|||||
|
INTERCEPT E-NEWSLETTER INTERCEPT eNews delivers product news & information updates right to your inbox. |
UNITED STATES RESIDENTS This site is intended for use by healthcare professionals outside of the United States only. If you are a resident of the United States, please see important information HERE. |
APPROVAL STATUS |
|
||


